That's a bit of a mis-nomer because a pop sets them up much better for a secondary. Among other benefits of a pop. Absence of a pop gives the impression of "failure" which takes awhile to overcome.
It depends, especially on the sector. Experimental Biotech companies will do many secondary offerings throughout their existence.
In this case the underwriter who controlled this IPO likely has what is known as a "green shoe". The green shoe is an agreement to sell more shares (up to 15%) after the IPO and they acquire them from the company at the IPO price. This means the bank could sell 15% more stock that wasn't part of the original IPO at current market prices and only have to pay the company the original IPO price. The company raises more money and the underwriter makes more profit. This happens when there is a successful IPO where the market prices the stock higher than the IPO price.
